In vitro and in vivo antifungal activity of amphotericin B lipid complex: Are phospholipases important?

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 767-771

  Swenson, Christine E ^a   Perkins, Walter R ^a   Roberts, Patricia ^a   Ahmad, Imran ^a   Stevens, Rachel ^a   Stevens, David A ^b   Janoff, Andrew S ^a  

^a Liposome Company Incorporated   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; PHOSPHOLIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG RESISTANCE; HYDROLYSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031956775     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.767     Document Type: Article

References (26)

1. Bhamra, R., A. Sa'ad, L. E. Bolcsak, A. S. Janoff, and C. E. Swenson. 1997. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats. Antimicrob. Agents Chemother. 41:886-892.
2. Birch, M., G. Robson, D. Law, and D. W. Denning. 1996. Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect. Immun. 64:751-755.
3. Calderone, R., R. Diamond, J.-M. Senet, J. Warmington, S. Filler, and J. E. Edwards. 1994. Host cell-fungal cell interactions. J. Med. Vet. Mycol. 32(Suppl. 1):151-168.
4. Clark, J. M., R. R. Whitney, S. J. Olsen, R. J. George, M. R. Swerdel, L. Kunselman, and D. P. Bonner. 1991. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob. Agents Chemother. 35:615-621.
5. Clemons, K. V., and D. A. Stevens. 1991. Comparative efficacies of amphotericin B lipid complex and amphotericin B deoxycholate suspension against murine blastomycosis. Antimicrob. Agents Chemother. 35:2144-2146.
6. Clemons, K. V., and D. A. Stevens. 1992. Efficacies of amphotericin B lipid complex (ABLC) and conventional amphotericin B against murine coccidioidomycosis. J. Antimicrob. Chemother. 30:353-363.
7. Dix, S. P., and J. R. Wingard. 1996. Amphotericin B lipid complex: review of safety, pharmacokinetics and efficacy. Drugs Today 32:411-416.
8. Filler, S. G., B. O. Ibe, A. S. Ibrahim, M. A. Ghannoum, J. U. Raj, and J. E. Edwards, Jr. 1994. Mechanism by which Candida albicans induces cell prostaglandin synthesis. Infect. Immun. 62:1064-1069.
9. Hanson, L. H., and D. A. Stevens. 1992. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob. Agents Chemother. 36:486-488.
10. Ibrahim, A. S., F. Mirbod, S. G. Filler, Y. Banno, G. T. Cole, Y. Kitajima, J. E. Edwards, Y. Nozawa, and M. A. Ghannoum. 1995. Evidence implicating phospholipase as a virulence factor of Candida albicans. Infect. Immun. 63:1993-1998.
11. Janoff, A. S., L. T. Boni, M. C. Popescu, S. R. Minchey, P. R. Cullis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, M. W. Tate, R. Mendelsohn, and D. Bonner. 1988. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc. Natl. Acad. Sci. USA 85:6122-6126.
12. Janoff, A. S., W. R. Perkins, S. L. Saletan, and C. E. Swenson. 1993. Amphotericin B lipid complex (ABLC®): a molecular rationale for the attenuation of amphotericin B related toxicities. J. Liposome Res. 3:451-471.
13. Minassian, B., R. K. Flamm, R. R. Whitney, L. Kunselman, L. Bender, R. Summerill, and D. P. Bonner. 1990. Decreased phospholipase activity in C. albicans is associated with increased MICs for amphotericin B lipid complex, abstr 847, p. 227. In Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society tor Microbiology, Washington, D.C.
14. Mitsutake, K., S. Kohno, Y. Miyazaki, T. Noda, H. Miyazaki, T. Miyazaki, M. Kaku, H. Koga, and K. Hara. 1994. In vitro and in vivo antifungal activities of liposomal amphotericin B and amphotericin B lipid complex. Mycopathologia 128:13-17.
15. National Committee for Clinical Laboratory Standards. 1992. NCCLS document M27P, vol. 12, no. 25. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standards. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Pahls, S., and A. Schaffner. 1994. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J. Infect. Dis. 169:1057-1061.
17. Perkins, W. R., S. R. Minchey, L. T. Boni, C. E. Swenson, M. C. Popescu, R. F. Pasternak, and A. S. Janoff. 1992. Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim. Biophys. Acta 1107:271-282.
18. Price, M. F., I. D. Wilkinson, and L. O. Gentry. 1982. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 20:7-14.
19. Ralph, E. D., A. M. Khazindar, K. R. Barber, and C. W. M. Grant. 1991. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob. Agents Chemother. 35:188-191.
20. Rex, J. H., M. A. Pfaller, M. G. Rinaldi, A. Polak, and J. N. Galgiani. 1993. Antifungal susceptibility testing. Clin. Microbiol. Rev. 6:367-381.
21. Stevens, D. A. 1996. Aspergillosis, p. 1830-1832. In J. C. Bennett and F. Plum (ed.), Cecil's textbook of medicine, 20th ed. The W. B. Saunders Co., New York, N.Y.
22. Swatek, F., C. Halde, M. G. Rinaldi, and H. J. Shadomy. 1985. Aspergillus species and other opportunistic saprophytic hyaline hyphomycetes, p. 584-594. In E. H. Lennette, A. Balows, W. J. Hausler, Jr., and H. J. Shadomy (ed.), Manual of clinical microbiology, 4th ed. American Society for Microbiology, Washington, D.C.
23. Vadas, P., J. Browning, J. Edelson, and W. Pruzanski. 1993. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J. Lipid Mediators 8:1-30.
24. Walsh, T. J., P. Whitcomb, S. Piscitelli, W. D. Figg, S. Hill, S. J. Chanock, P. Jarosinski, R. Gupta, and P. A. Pizzo. 1997. Safety, tolerance and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. 41:1944-1948.
25. Wingard, J. R. 1997. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant. 19:343-347.
26. Zar, J. H. 1974. Biostatistical analysis. Prentice-Hall, Inc., Englewood Cliffs, N.J.